Vedanta Biosciences (normalized profile)
Vedanta Biosciences develops microbiome-based oral therapies centered on defined bacterial consortia to address serious gastrointestinal diseases. The company advances live biotherapeutic products through proprietary platforms, integrating discovery, clinical, and fully integrated commercial-scale manufacturing. Its approach emphasizes defined, standardized bacterial products designed to restore a healthy microbiome and address unmet needs such as recurrent Clostridioides difficile infection and antimicrobial-resistant infections.
Industries
N/A
Products
Oral live biotherapeutic product candidate; defined bacterial consortium of eight strains designed for prevention of recurrent Clostridioides difficile infection. Undergoing Phase 3 clinical evaluation.
Preclinical oral live biotherapeutic, defined bacterial consortium targeting the prevention of Gram-negative antimicrobial-resistant (AMR) infections, including carbapenem-resistant and ESBL-producing Enterobacteriaceae.
Oral live biotherapeutic product candidate; defined bacterial consortium of eight strains designed for prevention of recurrent Clostridioides difficile infection. Undergoing Phase 3 clinical evaluation.
Preclinical oral live biotherapeutic, defined bacterial consortium targeting the prevention of Gram-negative antimicrobial-resistant (AMR) infections, including carbapenem-resistant and ESBL-producing Enterobacteriaceae.
Expertise Areas
- Microbiome-based drug development
- Clinical trial management for GI therapeutics
- Manufacturing of live biotherapeutic products
- Gastroenterology and infectious diseases
Key Technologies
- Defined bacterial consortia
- Live biotherapeutic products
- CGMP manufacturing of live biologics
- Large-scale bacterial strain libraries
Key People
Founder, Chief Executive Officer
Chief Operating Officer
Chief Medical Officer (Consultant)
Chief Financial Officer (Consultant)
SVP, Regulatory Affairs
SVP, Head of Commercial
Founder, Chief Executive Officer
Chief Operating Officer
Chief Medical Officer (Consultant)
Chief Financial Officer (Consultant)
SVP, Regulatory Affairs
SVP, Head of Commercial
News & Updates
Pioneered in-house CGMP manufacturing of defined bacterial consortia suitable for Phase 3 clinical evaluation.
Published clinical trial results for defined bacterial consortium therapy in JAMA, reporting reduced CDI recurrence rates.
Article in Cell Host & Microbe on VE303 strain colonization and microbiota changes in healthy adults.
Nature Medicine publication on multi-omic analysis of defined bacterial consortia for CDI.
Nature publication demonstrating the ecological decolonization of Enterobacteriaceae by commensal consortia.
Phase 1 trial for live biotherapeutic targeting inflammatory bowel disease, published in the European Journal of Gastroenterology & Hepatology.
Pioneered in-house CGMP manufacturing of defined bacterial consortia suitable for Phase 3 clinical evaluation.
Published clinical trial results for defined bacterial consortium therapy in JAMA, reporting reduced CDI recurrence rates.
Article in Cell Host & Microbe on VE303 strain colonization and microbiota changes in healthy adults.
Nature Medicine publication on multi-omic analysis of defined bacterial consortia for CDI.
Nature publication demonstrating the ecological decolonization of Enterobacteriaceae by commensal consortia.
Phase 1 trial for live biotherapeutic targeting inflammatory bowel disease, published in the European Journal of Gastroenterology & Hepatology.